48 related articles for article (PubMed ID: 11078500)
1. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.
Cokgor I; Akabani G; Kuan CT; Friedman HS; Friedman AH; Coleman RE; McLendon RE; Bigner SH; Zhao XG; Garcia-Turner AM; Pegram CN; Wikstrand CJ; Shafman TD; Herndon JE; Provenzale JM; Zalutsky MR; Bigner DD
J Clin Oncol; 2000 Nov; 18(22):3862-72. PubMed ID: 11078500
[TBL] [Abstract][Full Text] [Related]
2. A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.
Reardon DA; Zalutsky MR; Akabani G; Coleman RE; Friedman AH; Herndon JE; McLendon RE; Pegram CN; Quinn JA; Rich JN; Vredenburgh JJ; Desjardins A; Guruangan S; Boulton S; Raynor RH; Dowell JM; Wong TZ; Zhao XG; Friedman HS; Bigner DD
Neuro Oncol; 2008 Apr; 10(2):182-9. PubMed ID: 18287339
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.
Zalutsky MR; Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Wong TZ; Bigner DD
J Nucl Med; 2008 Jan; 49(1):30-8. PubMed ID: 18077533
[TBL] [Abstract][Full Text] [Related]
4. Distribution of labelled anti-tenascin antibodies and fragments after injection into intact or partly resected C6-gliomas in rats.
Goetz CM; Rachinger W; Decker M; Gildehaus FJ; Stocker S; Jung G; Tatsch K; Tonn JC; Reulen HJ
Cancer Immunol Immunother; 2005 Apr; 54(4):337-44. PubMed ID: 15449040
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; Cokgor I; McLendon RE; Pegram CN; Provenzale JM; Quinn JA; Rich JN; Regalado LV; Sampson JH; Shafman TD; Wikstrand CJ; Wong TZ; Zhao XG; Zalutsky MR; Bigner DD
J Clin Oncol; 2002 Mar; 20(5):1389-97. PubMed ID: 11870184
[TBL] [Abstract][Full Text] [Related]
6. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; McLendon RE; Pegram CN; Provenzale JM; Quinn JA; Rich JN; Vredenburgh JJ; Desjardins A; Gururangan S; Badruddoja M; Dowell JM; Wong TZ; Zhao XG; Zalutsky MR; Bigner DD
J Clin Oncol; 2006 Jan; 24(1):115-22. PubMed ID: 16382120
[TBL] [Abstract][Full Text] [Related]
7. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.
Akabani G; Reardon DA; Coleman RE; Wong TZ; Metzler SD; Bowsher JE; Barboriak DP; Provenzale JM; Greer KL; DeLong D; Friedman HS; Friedman AH; Zhao XG; Pegram CN; McLendon RE; Bigner DD; Zalutsky MR
J Nucl Med; 2005 Jun; 46(6):1042-51. PubMed ID: 15937318
[TBL] [Abstract][Full Text] [Related]
8. Radiolabeled Antibodies for Cancer Imaging and Therapy.
Parakh S; Lee ST; Gan HK; Scott AM
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326605
[TBL] [Abstract][Full Text] [Related]
9. A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma.
Bolcaen J; Kleynhans J; Nair S; Verhoeven J; Goethals I; Sathekge M; Vandevoorde C; Ebenhan T
Theranostics; 2021; 11(16):7911-7947. PubMed ID: 34335972
[TBL] [Abstract][Full Text] [Related]
10. Tenascin-C promotes epithelial-to-mesenchymal transition and the mTOR signaling pathway in nasopharyngeal carcinoma.
Cheng X; Li F; Tao Z
Oncol Lett; 2021 Jul; 22(1):570. PubMed ID: 34113398
[TBL] [Abstract][Full Text] [Related]
11. Beyond the Barrier: Targeted Radionuclide Therapy in Brain Tumors and Metastases.
Puttemans J; Lahoutte T; D'Huyvetter M; Devoogdt N
Pharmaceutics; 2019 Aug; 11(8):. PubMed ID: 31374991
[TBL] [Abstract][Full Text] [Related]
12. Potential for Nuclear Medicine Therapy for Glioblastoma Treatment.
Bailly C; Vidal A; Bonnemaire C; Kraeber-Bodéré F; Chérel M; Pallardy A; Rousseau C; Garcion E; Lacoeuille F; Hindré F; Valable S; Bernaudin M; Bodet-Milin C; Bourgeois M
Front Pharmacol; 2019; 10():772. PubMed ID: 31354487
[TBL] [Abstract][Full Text] [Related]
13. Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.
Gan HK; van den Bent M; Lassman AB; Reardon DA; Scott AM
Nat Rev Clin Oncol; 2017 Nov; 14(11):695-707. PubMed ID: 28675164
[TBL] [Abstract][Full Text] [Related]
14. Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.
Sawyer AJ; Kyriakides TR
Adv Drug Deliv Rev; 2016 Feb; 97():56-68. PubMed ID: 26763408
[TBL] [Abstract][Full Text] [Related]
15. Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs.
von Neubeck C; Seidlitz A; Kitzler HH; Beuthien-Baumann B; Krause M
Br J Radiol; 2015 Sep; 88(1053):20150354. PubMed ID: 26159214
[TBL] [Abstract][Full Text] [Related]
16. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence.
Barker HE; Paget JT; Khan AA; Harrington KJ
Nat Rev Cancer; 2015 Jul; 15(7):409-25. PubMed ID: 26105538
[TBL] [Abstract][Full Text] [Related]
17. Tenascin-C expression is associated with poor prognosis in hepatocellular carcinoma (HCC) patients and the inflammatory cytokine TNF-α-induced TNC expression promotes migration in HCC cells.
Nong Y; Wu D; Lin Y; Zhang Y; Bai L; Tang H
Am J Cancer Res; 2015; 5(2):782-91. PubMed ID: 25973315
[TBL] [Abstract][Full Text] [Related]
18. Tenascin-C: Form versus function.
Giblin SP; Midwood KS
Cell Adh Migr; 2015; 9(1-2):48-82. PubMed ID: 25482829
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA-substance P--results from a phase I study.
Cordier D; Forrer F; Kneifel S; Sailer M; Mariani L; Mäcke H; Müller-Brand J; Merlo A
J Neurooncol; 2010 Oct; 100(1):129-36. PubMed ID: 20217458
[TBL] [Abstract][Full Text] [Related]
20. Current available therapies and future directions in the treatment of malignant gliomas.
Desjardins A; Reardon DA; Vredenburgh JJ
Biologics; 2009; 3():15-25. PubMed ID: 19707392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
